National Cancer Institute, Research Contracts Branch, PSAS, 6120 Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227

B -- SPECIAL STUDIES AND ANALYSIS-NOT R&D (PILOT STUDY FOR COLORECTAL CANCER SCREENING SURVEILLANCE SOL RFQ-NCI-80187 DUE 081998 POC Cynthia Brown, Purchasing Agent, 301-402-4509, Todd Cole, Contracting Officer The National Institutes of Health, National Cancer Institute(NCI), Division of Cancer Control and Population Science, Cancer Surveillance Research Program(CSRP) intends to procure services from the Center for Health Studies, Group Health Cooperative (GHC), 1730 Minor Avenue, Suite #1600, Seattle, WA., 98101. BACKGROUND: The CSRP's overall goal is to support a study of pilot methods for conducting surveillance of colorectal cancer (CRC) screening in a defined population of patients enrolled in a managed care setting. Monitoring the performance of cancer screening in the general population is an important component of the CSRP. CSRP has developed a national system for monitoring the perforance of breast cancer screening, the NCI Breast Cancer Surveillance Consortium. In order to accomplish this goal CSRP supports and coordinates studies in which data on community mammography is linked to data on diagnostic follow-up procedures and data, from population-based cancer registries, on cancer stage-at-diagnosis and survival. With the advent of Medicare coverage for CRC screening and renewed attention to CRC screening guidelines and education, there is a need to develop a similar monitoring system for CRC screening. The prerequisite for doing this to to understand the process and structure of CRC screening and to demonstrate that it is possible to link the data on initial colorectal cancer screening to subsequent diagnostic procedures and data on cancer state-at-diagnosis and survival. STUDY DATA: Group Health Cooperative (GHC) has unique capabilities to conduct this pilot study. As a large staff model health maintenance organization, GHC has access to a defined population, to a clinical and financial data system for tracking CRC screening procedures. In addition, GHC is also located in the Seattle SEER cancer registry area and can link its records to the Seattle SEER. GHC has an established core data collection that will serve as a platform for this study. GHC has also conducted a number of studies related to CRC screening which provides it with experience and capabilities for this study, including a study of diagnostic follow-up subsequent to fecal occult blood testing, a study on the accuracy of self-reported fecal occult blood testing, and study of factors related to CRC screening participation among older women enrolled in GHC. GHC, a staff-model HMO serving over 420,000 members in Western Washington, has proven to be a strong site for cancer control research because enrollees receive almost all of their care within the GHC system. GHC maintains extensive automated information systems on clinical care linked by a unique Medical History number and organized in SAS. The Seattle SEER accrues approximately 1,800 cases of colorectal cancer each year from a population of 3,300,000. SEER give GHC an extract from its data base of all cases which are marked as diagnosed and/or treated at GHC. Using methods established under the Breast Cancer Surveillance project, individuals screened at GHC who were subsequently diagnosed with cancer outside of the GHC system following termination of enrollment may also be identified. The specific aims of this study are: 1)To pilot methods for establishing a prospective registry of fecal occult blood (FOB) tests, sigmoidoscopy, and colonoscopy procedures that includes information on indication for examination, (e.e., screening or symptomatic). 2) to investigate outcomes of screening and diagnostic studies; 3) to identify and review records from cases of CRC diagnosed in the GHC population 1993-1997 to compare extent of disease at diagnosis and clinical outcomes among screen-detected and clinically diagnosed cases. CONTRACTOR REQUREMENTS: The period of performance shall begin October 1, 1998 and end one(1) year later. Quarterly progress reports to NCI are required. A draft final report to NCI will be due August 1, 1999. A final report to NCI shall be due September 30, 1999. A final report shall take the form of the following: 1) A report to NCI describing data and methods used in the study and results of the study in terms of describing the feasiblity of CRC screening surveillance on a larger scale, resources and organization required for such surveillance, and generalizability of this approach to non-HMO settings; 2.) Data results to the specific aims of the study presented in table form and also made available to NCI in appropriate electronic form, such as SAS data files or electronic spreadsheet data files; 3.) One or more draft manuscripts to be submitted for publication in peer-reviewed journals, after review and approval by the NCI contracting officer. This notice of intent is not a request for competitive proposals Group Health Cooperative is the only source known to NCI that can meet the above requirements. However, if any other interested party believes it can meet the above requirements, it may submit a statement of capabilities to the attention of Cynthia Brown, Purchasing Agent at the above address. Information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirements. Capability statements must be received in the contracting ofice by 3:00 p.m. EST on August 19, 1998. This solicitation, RFQ-NCI-80187, is not set-aside for small businesses; however the Standard Industrial Classification Code is 8733. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Posted 07/31/98 (W-SN231078). (0212)

Loren Data Corp. http://www.ld.com (SYN# 0013 19980804\B-0005.SOL)